A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16

Oncogene

Volumn 25, Issue 50, 2006, Pages 6648-6659

  Billottet, C ^a   Grandage, V L ^b   Gale, R E ^b   Quattropani, A ^c   Rommel, C ^c   Vanhaesebroeck, B ^a,d   Khwaja, A ^b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Akt; AML; NF B; p110 ; PI3K; PKB; VP16

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; IC 87114; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN P110; UNCLASSIFIED DRUG; ADENINE; DRUG DERIVATIVE; ISOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CD PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG INHIBITION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LEUKOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; APOPTOSIS; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYMOLOGY; EVALUATION; IN VITRO STUDY; METABOLISM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENINE; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; ENZYME ACTIVATION; ETOPOSIDE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; NF-KAPPA B; PROTEIN ISOFORMS; QUINAZOLINES;

EID: 33750459743     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209670     Document Type: Article

References (67)

1. Aggerholm A, Gronbaek K, Guldberg P, Hokland P. (2000). Eur J Haematol 65: 109-113.
2. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C et al. (2004). Nature 431: 1007-1011.
3. Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, Poggi V et al. (2005). Blood 106: 1400-1406.
4. Bayascas JR, Alessi DR. (2005). Mol Cell 18: 143-145.
5. Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C et al. (2005). Blood 107: 642-650.
6. Bousquet M, Recher C, Queleen C, Demur C, Payrastre B, Brousset P. (2005). Br J Haematol 131: 411-413.
7. Brennan P, Babbage JW, Burgering BM, Groner B, Reif K, Cantrell DA. (1997). Immunity 7: 679-689.
8. Brognard J, Clark AS, Ni Y, Dennis PA. (2001). Cancer Res 61: 3986-3997.
9. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J et al. (2005). Nat Med 11: 936-943.
10. Cantley LC. (2002). Science 296: 1655-1657.
11. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW et al. (1997). J Biol Chem 272: 19236-19241.
12. Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, Ko YW et al. (2003). Br J Haematol 122: 454-456.
13. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A et al. (2002). J Exp Med 196: 753-763.
14. Cornillet-Lefebvre P, Cuccuini W, Bardet V, Tamburini J, Gillot L, Ifrah N et al. (2005). Leukemia 20: 374-376.
15. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. (2000a). Curr Biol 10: 1201-1204.
16. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW et al. (2000b). Mol Cell Biol 20: 9138-9148.
17. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. (2004). Cancer Treat Rev 30: 193-204.
18. Fruman DA. (2004). Biochem Soc Trans 32: 315-319.
19. Grandage VL, Gale RE, Linch DC, Khwaja A. (2005). Leukemia 19: 586-594.
20. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. (2001). Blood 98: 2301-2307.
21. Hande KR. (1998). Eur J Cancer 34: 1514-1521.
22. Hayakaa M, Kaizawa H, Kawaguchi KI, Matsuda K, Ishikawa N, Koizumi T et al. (2002) (Patent number: US 6403588 B1).
23. Hill K, Welti S, Yu J, Murray JT, Yip SC, Condeelis JS et al. (2000). J Biol Chem 275: 3741-3744.
24. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE et al. (2005). Nat Med 11: 507-514.
25. Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, Carpino N et al. (2002). Mol Cell Biol 22: 8580-8591.
26. Kang S, Bader AG, Zhao L, Vogt PK. (2005). Cell Cycle 4: 578-581.
27. Kaspers GJ, Veerman AJ. (2003). Recent Results Cancer Res 161: 196-220.
28. Kelly LM, Gilliland DG. (2002). Annu Rev Genomics Hum Genet 3: 179-198.
29. Knight ZA, Chiang GG, Alaimo PJ, Kenski DM, Ho CB, Coan K et al. (2004). Bioorg Med Chem 12: 4749-4759.
30. Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T. (2004). Leukemia 18: 1438-1440.
31. Luo J, Manning BD, Cantley LC. (2003a). Cancer Cell 4: 257-262.
32. Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K et al. (2003b). Leukemia 17: 1-8.
33. Medema RH, Kops GJ, Bos JL, Burgering BM. (2000). Nature 404: 782-787.
34. Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK et al. (2003). Leukemia 17: 995-997.
35. Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H et al. (2005). Leukemia 19: 1361-1366.
36. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA et al. (1994). Blood 83: 1603-1611.
37. Nicholson KM, Anderson NG. (2002). Cell Signal 14: 381-395.
38. Odero MD, Zeleznik-Le NJ, Chinwalla V, Rowley JD. (2000). Genes Chromosomes Cancer 29: 333-338.
39. Okkenhaug K, Bilancio A, Emery JL, Vanhaesebroeck B. (2004). Biochem Soc Trans 32: 332-335.
40. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E et al. (2002). Science 297: 1031-1034.
41. Okkenhaug K, Vanhaesebroeck B. (2003). Nat Rev Immunol 3: 317-330.
42. Parsons R. (2004). Semin Cell Dev Biol 15: 171-176.
43. Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG. (2004). J Immunol 173: 2236-2240.
44. Robertson AJ, Jackson S, Kenche V, Yaip C, Parbaharan H, Thompson P. (2001). International Patent Application (Patent Number: WO 0153266 A1).
45. Roche S, Koegl M, Courtneidge SA. (1994). Proc Natl Acad Sci USA 91: 9185-9189.
46. Sadhu C, Dick K, Treiberg J, Sowell CG, Kesicki EA, Oliver A. (2001). International Patent Application (Patent Number: WO 0181346 A2).
47. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. (2003). J Immunol 170: 2647-2654.
48. Samuels Y, Velculescu VE. (2004). Cell Cycle 3: 1221-1224.
49. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). Science 304: 554.
50. Sargent JM. (2003). Recent Results Cancer Res 161: 13-25.
51. Sawyer C, Sturge J, Bennett DC, O'Hare MJ, Allen WE, Bain J et al. (2003). Cancer Res 63: 1667-1675.
52. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C et al. (1999). Nat Genet 21: 99-102.
53. Simpson L, Parsons R. (2001). Exp Cell Res 264: 29-41.
54. Stirewalt DL, Radich JP. (2003). Nat Rev Cancer 3: 650-665.
55. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F et al. (2005). Blood 106: 1063-1066.
56. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. (1997a). Trends Biochem Sci 22: 267-272.
57. Vanhaesebroeck B, Waterfield MD. (1999). Exp Cell Res 253: 239-254.
58. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ et al. (1997b). Proc Natl Acad Sci USA 94: 4330-4335.
59. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. (2000). Mol Cell Biol 20: 5010-5018.
60. Vivanco I, Sawyers CL. (2002). Nat Rev Cancer 2: 489-501.
61. Wantzin GL, Killmann SA. (1977). Eur J Cancer 13: 647-655.
62. Warner JK, Wang JC, Hope KJ, Jin L, Dick JE. (2004). Oncogene 23: 7164-7177.
63. Watts MJ, Somervaille TC, Ings SJ, Ahmed F, Khwaja A, Yong K et al. (2002). Br J Haematol 118: 117-123.
64. West KA, Castillo SS, Dennis PA. (2002). Drug Resist Updat 5: 234-248.
65. Wymann MP, Zvelebil M, Laffargue M. (2003). Trends Pharmacol Sci 24: 366-376.
66. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. (2003). Blood 102: 972-980.
67. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M et al. (2004). Leukemia 18: 267-275.